Cilostazol is an antiplatelet drug often used in Asia; however, it is rarely used in the western hemisphere, particularly for stroke patients. Further studies of cilostazol in other ethnicities are required to prove or disprove whether this drug is also beneficial in non-Asian populations.
KwonSUChoYJKooJS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke2005; 36:782–6.
6.
WongKSLiHLamWWChanYLKayR. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke2002; 33:532–6.
7.
KimuraKKazuiSMinematsuKYamaguchiT. Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis2004; 18:47–56.
8.
WuBLinSHaoZ. Proportion, risk factors and outcome of lacunar infarction: a hospital-based study in a Chinese population. Cerebrovasc Dis2010; 29:181–7.
9.
KimYDChoiHYChoHJ. Increasing frequency and burden of cerebral artery atherosclerosis in Korean stroke patients. Yonsei Med J2010; 51:318–25.
10.
ShinoharaYRegional differences in incidence and management of stroke – is there any difference between Western and Japanese guidelines on antiplatelet therapy?Cerebrovasc Dis2006; 21 (Suppl. 1): 17–24.
11.
ShinoharaYGotohFTohgiH. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis2008; 26:63–70.
12.
NonakaYTsurumaKShimazawaMYoshimuraSIwamaTHaraH. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett2009; 452:156–61.
13.
LeeJHKimKYLeeYK. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther2004; 308:896–903.
14.
ZhaoDLiuJWangW. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke2008; 39:1668–74.
15.
ThammarojJSubramaniamVBhattacharyaJJ. Stroke in Asia. Neuroimaging Clin N Am2005; 15:273–82, ix–x.
16.
WooKSKimBRKimJE. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med2010; 30:460–8.
17.
HoshinoKHoriuchiHTadaT. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J2009; 73:336–42.
18.
FurutaTShiraiNSugimotoMNakamuraAHishidaAIshizakiT. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet2005; 20:153–67.
19.
ShinoharaY. Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis2006; 22:57–60.
20.
OhkuboTChapmanNNealBWoodwardMOmaeTChalmersJ. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med2004; 169:1041–5.
21.
StoneWMDemaerschalkBMFowlRJMoneySR. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. J Stroke Cerebrovasc Dis2008; 17:129–33.
